Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.

Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

Friday, September 21, 2018

Cardurion Pharmaceuticals a biotechnology company focused on the development of novel nextgeneration therapeutics for the treatment of cardiovascular diseases today announced that the US Food and Drug Administration FDA has accepted its Investigational New Drug Application IND for CRD733 a Phosphodi..

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases

Friday, September 21, 2018

Emergex Vaccines Holding Limited Emergex a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases today announces that it has signed a Memorandum of Understanding MoU with Brazilbased Oswaldo Cruz Foundation Fiocruz for the development of..

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD

Thursday, September 20, 2018

Adverum Biotechnologies Inc a clinicalstage gene therapy company targeting unmet medical needs in serious rare and ocular diseases today announced the US Food and Drug Administration FDA has granted Fast Track designation for ADVM022 ADVM022 is a novel gene therapy candidate for the treatment of wet..

Propanc Biopharma Enters into Research Collaboration Agreement with the University of Jaén

Thursday, September 20, 2018

Propanc Biopharma Inc a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic ovarian and colorectal cancers today announced the execution of a research collaboration agreement with the Un..

Valeo Pharma and Besins Healthcare Announce Partnership for Utrogestan in Canada

Wednesday, September 19, 2018

Valeo Pharma Inc a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products and Besins Healthcare a global pharmaceutical company world leader in novel therapies for gynecology and andrology today announced a strategic agreement to commercialize Utroges..

LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics

Wednesday, September 19, 2018

LEO Pharma AS a global leader in medical dermatology and MorphoSys AG today announced an expansion of their existing strategic alliance to include peptidederived therapeutics The objective of the alliance is to identify novel peptidederived therapeutics for unmet medical needs that will be valuable ..

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

Tuesday, September 18, 2018

CRISPR Therapeutics a biopharmaceutical company focused on developing transformative genebased medicines for serious diseases and ViaCyte Inc a privately held regenerative medicine company today announced a collaboration focused on the discovery development and commercialization of geneedited alloge..

Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate

Tuesday, September 18, 2018

Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation for North American rights to Samumed39s SM04646 being developed for the treatment of idiopathic pulmonary fibrosis IPF Deal terms include 10 million upfront plus up to 340 million in developmental milestones ..

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

Monday, September 17, 2018

Halozyme Therapeutics Inc today announced that Roche has received approval from Health Canada for a subcutaneous SC formulation of trastuzumab Herceptin SC for the treatment of patients with HER2positive breast cancer This is a coformulation with Halozyme39s proprietary recombinant human hyaluronida..

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

Saturday, September 15, 2018

Allergan plc a leading global pharmaceutical company today announced it has agreed to acquire Bonti Inc a privately held clinicalstage biotechnology company focused on the development and commercialization of novel fastacting neurotoxin programs for aesthetic and therapeutic applications Followin..